# PsA Treatment With hOKT3γ1 (Ala-Ala)

> **NCT00239720** · PHASE2 · TERMINATED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 4 (actual)

## Conditions studied

- Arthritis, Psoriatic

## Interventions

- **DRUG:** hOKT3gamma1(Ala-Ala)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00239720
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-03-16
- **Primary completion:** 2006-12
- **Final completion:** 2008-06-25
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Study team decision-impact(s) of change in hOKT3γ1 (Ala-Ala) manufacturer during study.
- **Last updated:** 2017-04-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00239720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00239720, "PsA Treatment With hOKT3γ1 (Ala-Ala)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00239720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*